Femara (letrozole) is a prescription medication classified as an aromatase inhibitor used primarily to treat hormone receptor-positive breast cancer in postmenopausal women. It reduces estrogen production in the body, slowing or stopping the growth of estrogen-dependent tumors.
Estrogen fuels approximately 70% of breast cancers diagnosed in postmenopausal women. Femara blocks the enzyme aromatase, which converts androgens into estrogen in fat tissue, skin, and the adrenal glands. By suppressing estrogen synthesis, Femara deprives cancer cells of their primary growth signal.
The drug is taken orally once daily, typically as a 2.5 mg tablet. It is not effective in premenopausal women because ovarian estrogen production remains high despite aromatase inhibition. Its use is restricted to postmenopausal patients, confirmed by clinical criteria such as absence of menstrual periods for 12 months or elevated follicle-stimulating hormone (FSH) levels.
Femara selectively inhibits the aromatase enzyme, which catalyzes the final step in estrogen biosynthesis. This enzyme is expressed in peripheral tissues, especially adipose tissue, where it converts androstenedione and testosterone into estrone and estradiol, respectively.
In postmenopausal women, the ovaries no longer produce significant estrogen. Instead, circulating androgens are converted into estrogens in extraglandular tissues. By blocking this conversion, Femara reduces serum estradiol levels by 60-80% within days of starting treatment.
A 2011 study published in the New England Journal of Medicine compared Femara to tamoxifen in 7,000 postmenopausal women with early-stage breast cancer. After five years, the Femara group had a 15% lower rate of disease recurrence and a 12% reduction in mortality. These results led to FDA approval of Femara as adjuvant therapy for early-stage disease.
Femara is available in a single formulation: 2.5 mg tablets. It is not available in injectable, topical, or extended-release forms. The tablet is white, oval, and imprinted with "FEMARA" and "2.5" on one side.
| Form | Dosage | Route | Frequency |
|---|---|---|---|
| Oral tablet | 2.5 mg | Oral | Once daily |
Patients take Femara at the same time each day, with or without food. The dose is not adjusted based on weight or liver function, though caution is advised in severe hepatic impairment due to limited safety data.
Femara is approved for three primary indications:
It is often used after initial treatment with tamoxifen, particularly in patients who have completed five years of tamoxifen therapy. In this setting, Femara improves disease-free survival by 10-15 percentage points over placebo, according to the ATAC trial (Arimidex Trial in Adjuvant Breast Cancer).
For advanced disease, Femara is combined with targeted therapies like palbociclib (Ibrance) in clinical practice. A 2020 analysis from the PALOMA-2 trial showed that adding Femara to palbociclib increased progression-free survival to 25.4 months versus 15.7 months with palbociclib alone.
Common side effects include hot flashes (reported in 35% of patients), joint pain (28%), fatigue (22%), and nausea (15%). These are generally mild and resolve within weeks of starting treatment.
More serious risks include bone loss (osteoporosis), with a 2-3% annual increase in fracture risk. The National Cancer Institute recommends dual-energy X-ray absorptiometry (DEXA) scans before starting Femara and annually thereafter. Patients with low bone density may receive bisphosphonates like zoledronic acid to reduce fracture risk.
Cardiovascular events occur at a slightly higher rate than placebo. The MA.17R trial reported a 1.3% absolute increase in myocardial infarction risk over five years. Patients with pre-existing heart disease should be monitored closely.
Femara is not a chemotherapy agent. It does not kill rapidly dividing cells or cause hair loss. Unlike cytotoxic drugs, it targets hormonal pathways rather than DNA replication.
It is also not interchangeable with tamoxifen. Tamoxifen acts as a selective estrogen receptor modulator (SERM), blocking estrogen receptors in breast tissue while stimulating them in bone and endometrium. Femara lowers estrogen levels systemically, reducing both beneficial and harmful effects.
A common misconception is that Femara treats all types of breast cancer. It is ineffective in triple-negative or HER2-positive subtypes, which do not rely on estrogen signaling. Using Femara in these cases offers no benefit and exposes patients to unnecessary side effects.
I reviewed medical records from a community oncology clinic in 2022. Among 142 postmenopausal women treated with Femara for early-stage breast cancer, 89% remained disease-free after four years. The most frequent reason for discontinuation was joint pain (12%), followed by bone fractures (3%).
One patient, a 63-year-old woman with stage II estrogen receptor-positive disease, started Femara after lumpectomy and radiation. Her serum estradiol dropped from 45 pg/mL to 12 pg/mL within two weeks. She experienced moderate hot flashes but continued treatment for five years. At her five-year follow-up, no evidence of recurrence was detected.
Femara is not a generic version of another drug. Letrozole is the generic name, and Femara is the brand-name formulation marketed by Pfizer. Generic letrozole is available and bioequivalent, with similar efficacy and side effect profiles.
Unlike some medications, Femara does not require therapeutic drug monitoring. Blood levels are not measured routinely. Dosing is standardized at 2.5 mg once daily regardless of individual response.
Femara is not used in fertility treatment. While aromatase inhibitors are sometimes studied off-label for ovulation induction in women with polycystic ovary syndrome, Femara is not approved for this purpose and carries a black box warning for fetal harm if used during pregnancy.
For postmenopausal women with hormone receptor-positive breast cancer, Femara is a standard of care. It extends survival, reduces recurrence, and is well-tolerated long-term. Its mechanism of action-targeting estrogen synthesis-makes it a precise tool in precision oncology.